We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $118M
This Fund
S&P 500
This Quarter Est. Return
+3.46%
1 Year Est. Return
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$343M
AUM Growth
-$50.3M
Cap. Flow
-$56.3M
Cap. Flow %
-16.41%
Top 10 Hldgs %
78.35%
Holding
286
New
92
Increased
41
Reduced
68
Closed
66

Sector Composition

Rank Sector Weight
1 Real Estate 24.12%
2 Healthcare 12.62%
3 Financials 1.65%
4 Technology 1.41%
5 Industrials 1.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VRTX icon
276
Vertex Pharmaceuticals
VRTX
$121B
-10,250
Closed -$1.86M
WIP icon
277
State Street SPDR FTSE International Government Inflation-Protected Bond ETF
WIP
$479M
-1,246
Closed -$68K
WST icon
278
West Pharmaceutical
WST
$23.1B
-219
Closed -$93K
XLC icon
279
State Street Communication Services Select Sector SPDR ETF
XLC
$21.9B
-2,117
Closed -$170K
ITCI
280
DELISTED
Intra-Cellular Therapies Inc.
ITCI
-4,000
Closed -$149K
BCEL
281
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
-60,000
Closed -$374K
GRCL
282
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
-17,000
Closed -$236K
DBTX
283
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
-37,500
Closed -$289K
RSX
284
DELISTED
VanEck Russia ETF
RSX
-4,006
Closed -$121K
OYST
285
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
-98,500
Closed -$1.17M
TRIL
286
DELISTED
Trillium Therapeutics Inc.
TRIL
-54,500
Closed -$957K

Similar funds

AlphaCentric Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, AlphaCentric Advisors held 286 positions worth $343M, down 13% from $393M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

AlphaCentric Advisors withdrew a net $56.3M in Q4 2021, closing 66 positions and reducing 68 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $1.86M position sold in full.

By sector, the portfolio is most concentrated in Real Estate at 24% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.

Against the trend, AlphaCentric Advisors opened a new position in Jazz Pharmaceuticals worth $1.27M.

  • AlphaCentric Advisors's largest Q4 2021 buy was Jazz Pharmaceuticals: 10,000 shares worth $1.27M.
  • AlphaCentric Advisors added most to iShares 1-3 Year Treasury Bond ETF in Q4 2021, an estimated $1.84M increase.
  • AlphaCentric Advisors's biggest Q4 2021 reduction was Vanguard Mortgage-Backed Securities ETF, cutting an estimated $30.4M.
  • AlphaCentric Advisors fully exited Vertex Pharmaceuticals in Q4 2021, selling an estimated $1.86M.
  • AlphaCentric Advisors's ten largest holdings make up 78% of its $343M portfolio in Q4 2021.
  • AlphaCentric Advisors opened 92 new positions and closed 66 in Q4 2021.
  • AlphaCentric Advisors's portfolio value fell 13% quarter-over-quarter to $343M.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.